IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/25/2025 | $2.00 | Underperform | Wedbush |
| 10/24/2025 | $30.00 | Outperform | Leerink Partners |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wedbush resumed coverage of ImageneBio with a rating of Underperform and set a new price target of $2.00
Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
3 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
3 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
3 - ImageneBio, Inc. (0001835579) (Issuer)
424B3 - ImageneBio, Inc. (0001835579) (Filer)
8-K - ImageneBio, Inc. (0001835579) (Filer)
8-K - ImageneBio, Inc. (0001835579) (Filer)
SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)
S-8 - ImageneBio, Inc. (0001835579) (Filer)
424B3 - ImageneBio, Inc. (0001835579) (Filer)
10-Q - ImageneBio, Inc. (0001835579) (Filer)
8-K - ImageneBio, Inc. (0001835579) (Filer)
8-K - ImageneBio, Inc. (0001835579) (Filer)
424B3 - ImageneBio, Inc. (0001835579) (Filer)
Fastest customizable press release news feed in the world
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007's unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory Skin Disease Summit (ISDS) Strengthened leadership team and board with addition of Dr. Kristin Yarema as Chief Executive Officer, Dr. Kurinji Pandiyan as Chief Strategy and Operations Officer, Dr. Renuka Sivendran as Chief Technical Officer, and Joe Slattery as an indepe
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " "Company")), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY Piper Sander 37th Annual Healthcare ConferenceFireside Chat: Thursday, December 4, 10:00am ESTNew York, NY To access the live webcasts or subsequent archived recordings of the presentation and f
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory ("I&I") diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio's recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the "Board") and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units ("RSUs") for 153,505 shares of common stock (together, the "Inducement Awards"). The Inducement
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ImageneBio, Inc. (0001835579) (Issuer)